Sinovac Biotech Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Sinovac Biotech Ltd.
COVID-19 Windfalls Carry Pharma Into Stormy Times: Key Takeaways From Scrip 100 And Outlook 2023
The past couple of years have generated important growth for the pharma industry thanks to its drugs and vaccines for COVID-19. But with the IRA, high inflation, rising interest rates and chilly public markets, biopharma faces challenges this year. Here, we summarize key messages from In Vivo’s Outlook 2023.
Pfizer Leads An Unusual Year For The Scrip 100
Pfizer catapulted back into the lead in the pharmaceutical rankings on the strength of COVID-19 revenues while BioNTech and Moderna both made the list for the first time.
Pandemic Drives China Surge In Asia 100 Sales
Notable new entrants moved into the Asia 100 this year, with growth catalyzed by COVID-19 vaccines.
China Winds Down 'COVID Zero' But Vaccine Fatigue, Other Worries Linger
Three years since the first cluster of SARS-CoV-2 infections were reported in Wuhan, China has finally put the first nail in the coffin of its strict "COVID Zero" policies. But as Beijing begins to relax its most restrictive rules, citizens remain concerned about ballooning infections, while a low vaccination rate among seniors and vaccine fatigue appear to be dimming hopes of a quick revitalization of the hard-hit economy and bruised consumer confidence.
- In Vitro Diagnostics
- Drug Delivery
- Implantable Devices
- Monitoring Equipment & Devices
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Beijing Kexing Bioproducts
- Sinovac Dalian Vaccine Technology Co., Ltd.
- Sinovac (Cayman) Limited
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.